BioMarin to Acquire Alesta for Rare Bone Disease Drug
BioMarin Pharmaceutical has agreed to acquire Alesta Therapeutics in a deal aimed at adding a potential new treatment for hypophosphatasia (HPP), a rare genetic bone disease, to its…
Read More...
Read More...
